PD0325901-O-C2-dioxolane

Target: This ligand targets MEK1/MAP2K1 and MEK2/MAP2K2 kinases in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for MEK1/MAP2K1 and MEK2/MAP2K2 kinases. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings MEK1/MAP2K1 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC Design for ERK Degradation: PD0325901-O-C2-dioxolane can be used as a kinase-binding ligand to build PROTACs that recruit an E3 ligase and promote selective degradation of ERK pathway components. This enables mechanistic studies of ERK turnover, pathway rewiring, and degradation-dependent phenotypes compared with conventional kinase inhibition.

• E3 Ligase Recruitment Optimization: The ligand can serve as a warhead scaffold for testing multiple E3 ligase recruiters, allowing systematic optimization of ternary complex formation and ubiquitination efficiency. Researchers can evaluate how linker length, attachment position, and conformational constraints influence ERK-target engagement and degradation kinetics.

• Mechanistic Studies of Pathway Turnover: PROTAC constructs incorporating PD0325901-O-C2-dioxolane can be applied to dissect how ERK signaling output changes when protein levels are actively reduced. Time-course degradation assays, ubiquitin-proteasome dependence, and rescue experiments can distinguish degradation-driven effects from transient occupancy.

• Comparative Profiling vs Inhibitors: Using this ligand in PROTAC platforms supports head-to-head comparisons with small-molecule ERK pathway inhibitors. Such studies can quantify differences in duration of pathway suppression, recovery dynamics, and downstream transcriptional responses, clarifying whether sustained degradation yields distinct biological outcomes.

• Target Selectivity and Off-Target Assessment: PD0325901-O-C2-dioxolane-based PROTACs can be leveraged to evaluate selectivity across related kinases and signaling nodes. Proteomics and immunoblot profiling can determine whether degradation is confined to the intended ERK-associated proteins or extends to off-target substrates, guiding refinement of ligand choice and PROTAC architecture.

PD0325901-O-C2-dioxolane is a MEK ligand derivative designed for MEK-directed degrader development. The O-C2-dioxolane modification indicates a defined oxygen-linked structural vector for linker exploration.

Structure: PD0325901-O-C2-dioxolane is a PD0325901-derived MEK ligand modified through an oxygen-linked C2 dioxolane-containing substituent. The cyclic acetal/dioxolane structural feature is intended to act as a derivatization or linker-oriented vector while maintaining the PD0325901-derived MEK-binding core.

Reactivity: The O-C2-dioxolane region should be treated as the principal derivatization vector for MEK-directed PROTAC construction. Linker strategies may use oxygen-containing, acetal-compatible, alkyl, PEG, carbamate, or amide-based designs, provided the PD0325901-derived MEK-binding core remains unmodified. CRBN, VHL, or IAP ligase ligands can be evaluated after confirming that the dioxolane-linked analog retains MEK1/2 engagement.